Celldex Therapeutics (CLDX) Other Accumulated Expenses (2010 - 2026)

Celldex Therapeutics' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 25.59% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 25.59% YoY), while the FY2025 annual figure was $1.2 million, up 30.57% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.2 million, roughly flat from $1.2 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $4.2 million in Q3 2023, with the low at $378000.0 in Q4 2023.
• The 5-year median for Other Accumulated Expenses is $1.2 million (2025), against an average of $1.7 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 296.42% in 2024, then slumped 74.68% in 2025.
• Celldex Therapeutics' Other Accumulated Expenses stood at $990000.0 in 2022, then tumbled by 61.82% to $378000.0 in 2023, then soared by 149.21% to $942000.0 in 2024, then soared by 30.57% to $1.2 million in 2025, then changed by 0.0% to $1.2 million in 2026.
• Business Quant data shows CLDX's Other Accumulated Expenses at $1.2 million in Q1 2026, $1.2 million in Q4 2025, and $930000.0 in Q3 2025.